Forum Topic Pharmaceutical
  • Conversation: Expanded EU approval for Takeda's Alunbrig

    • April 8, 2020 2:36 PM BST
      • Post(s)

      Expanded EU approval for Takeda's Alunbrig

      European regulators have expanded the scope of Alunbrig (brigatinib) to include its use as a monotherapy for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) in the first-line setting.
      The approval is based on results from the Phase III ALTA-1L trial, which showed that the drug demonstrated superiority in this treatment setting compared to crizotinib with significant anti-tumor activity observed in patients with baseline brain metastases.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel